tirzepatide побочные эффекты Тирзепатид: основные исследования в области

Rok Herman of the University Medical Centre Ljubljana in Slovenia

In 2026 and beyond, pharma will invent success systematically-and AI is the platform

Similarly, a post-hoc analysis of SURPASS-1, enrolling 478 patients with T2D, found that all doses of tirzepatide as monotherapy increased insulin sensitivity compared to placebo, as suggested by the decreases in HOMA2-IR by 923% (vs +14.7% with placebo) and fasting insulin levels by 212% (vs +15%) and the increase in adiponectin by 1623% (vs 0.2%) and IGFBP-2 by 3870% (vs +4.1%) at 40 weeks [76]

10.1007/s13238-018-0546-3 44 SunL.ShangB.LvS.LiuG.WuQ.GengY

Weeks 9-12: 7.5mg (0.75mL or 75 units)